{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:07:59Z","timestamp":1790964479210,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.esmoop.2024.104083","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:57:33Z","timestamp":1733867853000},"page":"104083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-7517","authenticated-orcid":false,"given":"H.","family":"Jourdain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di Meglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Desplas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Haddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10286","key":"10.1016\/j.esmoop.2024.104083_bib1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"10087","key":"10.1016\/j.esmoop.2024.104083_bib2","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2024.104083_bib3","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.104083_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10390","key":"10.1016\/j.esmoop.2024.104083_bib5","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmoop.2024.104083_bib6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104083_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104083_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2024.104083_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101608","article-title":"Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure","volume":"8","author":"Antonarelli","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.104083_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study","volume":"29","author":"Botticelli","year":"2024","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.esmoop.2024.104083_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7168","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: real-life data from the temporary use authorization program in France","volume":"13","author":"Petit","year":"2024","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104083_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102995","article-title":"The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients\u2014a multicenter real-world analysis","volume":"9","author":"Dannehl","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.104083_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.104083_bib14","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev \u00c9pid\u00e9miol Sant\u00e9 Publique"},{"key":"10.1016\/j.esmoop.2024.104083_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/13524585231223395","article-title":"Use of multiple sclerosis disease-modifying therapies during pregnancy in France: nationwide study between 2010 and 2021","volume":"30","author":"Swital","year":"2024","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104083_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003531","article-title":"Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System","volume":"10","author":"Jourdain","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.esmoop.2024.104083_bib17","article-title":"Use of progestogens and the risk of intracranial meningioma: national case-control study","volume":"384","author":"Roland","year":"2024","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.esmoop.2024.104083_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9429","article-title":"Medically assisted reproduction and risk of cancer among offspring","volume":"7","author":"Rios","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2024.104083_bib19","article-title":"Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System","volume":"4","author":"Jourdain","year":"2024","journal-title":"ESMO Real World Data Digital Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.104083_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/sim.1589","article-title":"Effects and non-effects of paired identical observations in comparing proportions with binary matched-pairs data","volume":"23","author":"Agresti","year":"2004","journal-title":"Stat Med"},{"issue":"10371","key":"10.1016\/j.esmoop.2024.104083_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2024.104083_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Annal Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2024.104083_bib24","first-page":"3275","article-title":"Adverse event profile differences between trastuzumab emtansine and trastuzumab deruxtecan: a real-world, pharmacovigilance study","volume":"14","author":"Liu","year":"2023","journal-title":"J\u00a0Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924018532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:44:09Z","timestamp":1736311449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924018532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2059702924018532"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104083","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.104083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104083"}}